Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy

被引:38
|
作者
Sainz-Esteban, Aurora [3 ]
Prasad, Vikas [1 ,2 ]
Schuchardt, Christiane [1 ,2 ]
Zachert, Carolin [1 ,2 ]
Manuel Carril, Jose [3 ]
Baum, Richard P. [1 ,2 ]
机构
[1] Zent Klin Bad Berka, Dept Nucl Med, D-99437 Bad Berka, Germany
[2] Zent Klin Bad Berka, Ctr PET CT, D-99437 Bad Berka, Germany
[3] Hosp Univ Marques de Valdecilla, Dept Nucl Med, Santander, Spain
关键词
Lu-177-DOTA-TATE; Dosimetry scan; Ga-68-DOTA-TATE; Neuroendocrine tumour; RADIOLABELED SOMATOSTATIN ANALOG; TYR(3) OCTREOTATE; BIODISTRIBUTION; SCINTIGRAPHY; AFFINITY; GA-68;
D O I
10.1007/s00259-011-2003-x
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Purpose The aim of the study was to compare sequential Lu-177-DOTA-TATE planar scans (Lu-177-DOTA-TATE) in patients with metastasized neuroendocrine tumours (NET) acquired during peptide receptor radionuclide therapy (PRRT) for dosimetry purposes with the pre-therapeutic Ga-68-DOTA-TATE positron emission tomography (PET)/CT (Ga-68-DOTA-TATE) maximum intensity projection (MIP) images obtained in the same patients concerning the sensitivity of the different methods. Methods A total of 44 patients (59 +/- 11 years old) with biopsy-proven NET underwent Ga-68-DOTA-TATE and Lu-177-DOTA-TATE imaging within 7.9 +/- 7.5 days between the two examinations. Lu-177-DOTA-TATE planar images were acquired at 0.5, 2, 24, 48 and 72 h post-injection; lesions were given a score from 0 to 4 depending on the uptake of the radiopharmaceutical (0 being lowest and 4 highest). The number of tumour lesions which were identified on Lu-177-DOTA-TATE scans (in relation to the acquisition time after injection of the therapeutic dose as well as with regard to the body region) was compared to those detected on Ga-68-DOTA-TATE studies obtained before PRRT. Results A total of 318 lesions were detected; 280 (88%) lesions were concordant. Among the discordant lesions, 29 were Ga-68-DOTA-TATE positive and Lu-177-DOTA-TATE negative, whereas 9 were Ga-68-DOTA-TATE negative and Lu-177-DOTA-TATE positive. The sensitivity, positive predictive value and accuracy for Lu-177-DOTA-TATE as compared to Ga-68-DOTA-TATE were 91, 97 and 88%, respectively. Significantly more lesions were seen on the delayed (72 h) Lu-177-DOTA-TATE images (91%) as compared to the immediate (30 min) images (68%). The highest concordance was observed for bone metastases (97%) and the lowest for head/neck lesions (75%). Concordant lesions (n=77; mean size 3.8 cm) were significantly larger than discordant lesions (n=38; mean size 1.6 cm) (p<0.05). No such significance was found for differences in maximum standardized uptake value (SUVmax). However, concordant liver lesions with a score from 1 to 3 in the 72-h (177)LuDOTA- TATE scan had a lower SUVmax (n=23; mean 10.9) than those metastases with a score of 4 (n=97; mean SUVmax 18) (p<0.05). Conclusion Although Lu-177-DOTA-TATE planar dosimetry scans exhibited a very good sensitivity for thedetection of metastases, they failed to pick up 9% of lesions seen on the Ga-68-DOTA-TATE PET/CT. Three-dimensional dosimetry using single photon emission computed tomography/CT could be applied to investigate this issue further. Delayed (72 h) images are most suitable for drawing regions of interest for dosimetric calculations.
引用
收藏
页码:501 / 511
页数:11
相关论文
共 50 条
  • [21] Significance of Ga-68-DOTA-TOC-PET/CT in prediction of survival of patients treated with Lu-177-DOTA-TATE
    Haslerud, Torjan
    Sabet, Amir
    Muckle, Marianne
    Guhlke, Stefan
    Ahmadzadehfar, Hojjat
    Biersack, Hans Juergen
    Ezziddin, Samer
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53
  • [22] Significance of Ga-68-DOTA-TOC-PET/CT in prediction of survival of patients treated with Lu-177-DOTA-TATE
    Haslerud, T. M.
    Sabet, A.
    Muckle, M.
    Ahmadzadehfar, H.
    Simon, B.
    Biersack, H.
    Samer, E.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2012, 39 : S333 - S334
  • [23] Safety and efficacy of peptide receptor radionuclide therapy with 177Lu-DOTA-EB-TATE in patients with metastatic neuroendocrine tumors
    Jiang, Yuanyuan
    Liu, Qingxing
    Wang, Guochang
    Sui, Huimin
    Wang, Rongxi
    Wang, Jiarou
    Zhang, Jingjing
    Zhu, Zhaohui
    Chen, Xiaoyuan
    THERANOSTICS, 2022, 12 (15): : 6437 - 6445
  • [24] Comparison of 68Ga-DOTA-JR11 PET/CT with (dosimetric) 177Lu-DOTA-JR11 SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy
    Krebs, S.
    O'Donoghue, J.
    Biegel, E.
    Beattie, B. J.
    Reidy, D.
    Bodei, L.
    Weber, W. A.
    Pandit-Taskar, N.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S63 - S64
  • [25] Lebanese experience with 68Ga-DOTA-TATE PET/CT in the diagnosis and management of Neuroendocrine tumors.
    Haidar, M.
    Chehade, F.
    Asmar, R.
    Jriege, M.
    Khoury, T.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S376 - S376
  • [26] 68Ga-DOTA-FAPI-46 PET/CT Imaging for Restaging in a Patient With Metastatic Pheochromocytoma Comparison With 68Ga-DOTA-TATE PET/CT
    Sahin, Rahime
    Baloglu, Mehmet Can
    Ergul, Nurhan
    Cermik, Tevfik Fikret
    Arslan, Esra
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (11) : e622 - e624
  • [27] An intrapatient comparison of 18FDG and 68Ga-DOTA-TATE PET/CT imaging in Patients with Gastrointestinal Neuroendocrine Neoplasm
    Yu, Jiangyuan
    Li, Nan
    Yang, Zhi
    JOURNAL OF NUCLEAR MEDICINE, 2017, 58
  • [28] An Intrapatient Comparison of 18FDG and 68Ga-DOTA-TATE PET/CT Imaging in Patients with Gastrointestinal Neuroendocrine Neoplasm
    Yu, J.
    Li, J.
    Zhang, P.
    Lu, M.
    Yang, Z.
    NEUROENDOCRINOLOGY, 2017, 105 : 177 - 177
  • [29] The theranostic somatostatin receptor antagonist pair 68Ga-OPS202/177Lu-OPS201 is superior to the agonist pair 68Ga-DOTA-TATE/177Lu-DOTA-TATE: a preclinical and clinical phase I/II study.
    Nicolas, G. P.
    Mansi, R.
    Kaufmann, J.
    Bouterfa, H.
    Maecke, H. R.
    Wild, D.
    Fani, M.
    JOURNAL OF NUCLEAR MEDICINE, 2015, 56 (02) : 14 - 14
  • [30] Treatment Planning in Neuroendocrine Tumors: Utilizing a Single Individual Time-Point [68Ga]Ga-DOTA-TATE PET/CT Measurement for [177Lu]Lu-DOTA-TATE Therapy
    Valentina, Vasic
    Gustafsson, Johan
    Yousefzadeh-Nowshahr, Elham
    Beer, Ambros
    Gleisner, Katarina Sjogreen
    Glatting, Gerhard
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65